Legal Scrutiny Grows for aTyr Pharma Over Alleged Misleading Statements and Class Actions

### Legal Challenges Mount for aTyr Pharma Amid Allegations of Misleading Statements

In recent developments, aTyr Pharma, Inc. faces significant legal scrutiny as multiple law firms announce class action lawsuits and investigations concerning potential violations of securities laws. The allegations primarily center on misleading statements related to the company's Phase 3 clinical trial results for its experimental drug, Efzofitimod, designed to treat pulmonary sarcoidosis. Investors who acquired aTyr's securities between January 16, 2025, and September 12, 2025, are encouraged to participate in the legal actions, as these lawsuits suggest that aTyr's management may have misrepresented critical information about the drug's efficacy and the trial's design, leading to investor losses when the truth emerged.

The Schall Law Firm has formally initiated a class action lawsuit, stating that aTyr and its executives allegedly made false claims about the forced taper study design. The lawsuit contends that the company falsely suggested that Efzofitimod could enable patients to completely discontinue steroid use. This misrepresentation is claimed to have concealed crucial details from investors, ultimately rendering aTyr's public statements materially misleading. In light of these allegations, the firm's announcement serves as a rallying point for affected shareholders, inviting them to explore their rights and potential compensation.

Additionally, the DJS Law Group is conducting its investigation into aTyr's disclosures following a significant announcement on September 15, 2025. The company reported that Efzofitimod failed to meet its primary endpoint in a late-stage study, resulting in an alarming 81% drop in stock value. This event has further fueled the scrutiny surrounding aTyr's communications and the integrity of its trial results. The DJS Law Group emphasizes the importance of protecting the claims of investors who have suffered losses, highlighting the critical nature of the ongoing investigations and potential litigation.

In a parallel development, the Law Offices of Howard G. Smith have also thrown their hat into the ring, inviting investors who experienced losses between November 7, 2024, and September 12, 2025, to lead a securities fraud class action lawsuit. The firm asserts that aTyr misled investors by failing to disclose vital information regarding the EFZO-FIT study, including the drug's inability to significantly reduce corticosteroid doses as previously claimed. With multiple legal avenues being explored, the situation could have profound implications for aTyr Pharma and its stakeholders, prompting increased caution among investors.

As these legal challenges unfold, aTyr Pharma's future may hinge on the outcomes of these lawsuits and the company's ability to address the concerns raised by investors and regulators alike.